×
About 158 results

ALLMedicine™ Diffuse Large Cell Lymphoma Center

Research & Reviews  45 results

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
https://clinicaltrials.gov/ct2/show/NCT05389423

Aug 5th, 2022 - Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV (PLWH) in the United States. Even in the modern era of antiretroviral therapy (ART), PLWH have an 11- to 17-fold higher risk of NHL than the general popu...

The Natural Estrogen Receptor Beta Agonist Silibinin as a Promising Therapeutic Tool in...
https://doi.org/10.21873/anticanres.15535
Anticancer Research; Ortona E, Locatelli SL et. al.

Jan 31st, 2022 - About 40% of patients with diffuse large cell lymphoma (DLBCL) still have a poor prognosis. Additionally, DLBCL patients treated with doxorubicin are at risk of cardiac failure. Growing evidence suggests an antitumor and cardioprotective activity ...

Diffuse Large B-Cell Lymphoma (DLBCL)
https://emedicine.medscape.com/article/202969-overview

May 6th, 2021 - Practice Essentials Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma, representing approximately 30% of non-Hodgkin lymphomas (NHLs), [1] and it is rapidly fatal if untreated. See the image below. Most cases respond to standard im...

Diffuse Large B-Cell Lymphoma (DLBCL)
http://emedicine.medscape.com/article/208318-overview

May 6th, 2021 - Practice Essentials Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma, representing approximately 30% of non-Hodgkin lymphomas (NHLs), [1] and it is rapidly fatal if untreated. See the image below. Most cases respond to standard im...

Diffuse Large B-Cell Lymphoma (DLBCL)
http://emedicine.medscape.com/article/202969-overview

May 6th, 2021 - Practice Essentials Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma, representing approximately 30% of non-Hodgkin lymphomas (NHLs), [1] and it is rapidly fatal if untreated. See the image below. Most cases respond to standard im...

see more →

Clinicaltrials.gov  13 results

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
https://clinicaltrials.gov/ct2/show/NCT05389423

Aug 5th, 2022 - Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV (PLWH) in the United States. Even in the modern era of antiretroviral therapy (ART), PLWH have an 11- to 17-fold higher risk of NHL than the general popu...

Autologous and Allogeneic Transplant for Relapsed Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00802113

Mar 27th, 2019 - Lymphomas are the third most common group of cancers in children and adolescents in the United States. While Hodgkin's Disease (HD) has been described for many years, some subtypes of the non-Hodgkin's Lymphomas (NHL) have only recently been descr...

Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00169468

Aug 23rd, 2018 - The association of the monoclonal antibody Rituximab to chemotherapy regimen of B-cell lymphoma is associated with an increase response rate and event free survival when compared to chemotherapy alone (Coiffier et al NEJM 2002). It has been observ...

Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00566228

Jul 9th, 2018 - OBJECTIVES: Primary Determine the therapeutic effect of instrument-driven lymphocyte enrichment of the autograft absolute lymphocyte count (A-ALC) compared to "standard autograft collection" as determined by progression-free survival post-transpla...

Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00088881

May 25th, 2017 - PRIMARY OBJECTIVES: I. To evaluate the complete response rate (CR) and functional CR rate in patients with previously untreated stage I (with at least 1 risk factor) or stage II CD20+ diffuse large cell lymphoma who receive therapy with R-CHOP fol...

see more →

News  5 results

Relapsed/Refractory DLBCL Paradigm Gains Chemotherapy-Free Option
https://www.onclive.com/view/relapsed-refractory-dlbcl-paradigm-gains-chemotherapy-free-option

Jan 3rd, 2022 - Treatment options for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) now include an alternative to chemotherapy. On July 31, 2020, the FDA granted an accelerated approval to tafasitamab-cxix (Monjuvi) in combination wit...

The Future Treatment of Follicular Lymphoma
https://www.onclive.com/view/the-future-treatment-of-follicular-lymphoma

Apr 2nd, 2021 - Transcript: Ian W. Flinn, MD, PhD: Peter, CAR T cells are now approved for the treatment of refractory diffuse large cell lymphoma with some really impressive activity and also some concerning toxicity. There are certainly trials that are ongo...

R/R DLBCL: Transplant Eligibility and R-CHOP
https://www.onclive.com/view/r-r-dlbcl-transplant-eligibility-and-r-chop

Apr 2nd, 2021 - Brian Hill, MD, PhD: The question often comes up: What percentage of patients are refractory or relapse after standard frontline therapy? Depending on the risk category, this could be as high as 30% or 35% of patients who initially respond to R-CH...

Spontaneous Remission in Diffuse Large Cell Lymphoma
https://www.staging.medscape.com/viewarticle/910051

Abstract and Introduction Abstract Background: Spontaneous remission in solid malignancies has been documented. However, spontaneous remission in aggressive diffuse large b cell lymphoma is exceedingly rare. Previous reports of lymphoma remission ...

Spontaneous Remission in Diffuse Large Cell Lymphoma
https://www.medscape.com/viewarticle/910051

Abstract and Introduction Abstract Background: Spontaneous remission in solid malignancies has been documented. However, spontaneous remission in aggressive diffuse large b cell lymphoma is exceedingly rare. Previous reports of lymphoma remission ...

see more →